In the past week, NMTC stock has gone down by 0.00%, with a monthly decline of -6.42% and a quarterly surge of 52.53%. The volatility ratio for the week is 11.10%, and the volatility levels for the last 30 days are 9.31% for NeuroOne Medical Technologies Corp The simple moving average for the past 20 days is -5.33% for NMTC’s stock, with a 13.69% simple moving average for the past 200 days.
Is It Worth Investing in NeuroOne Medical Technologies Corp (NASDAQ: NMTC) Right Now?
Additionally, the 36-month beta value for NMTC is 0.64. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for NMTC is 26.76M and currently, short sellers hold a 0.76% ratio of that float. The average trading volume of NMTC on March 14, 2025 was 245.21K shares.
NMTC) stock’s latest price update
NeuroOne Medical Technologies Corp (NASDAQ: NMTC)’s stock price has gone rise by 7.08 in comparison to its previous close of 0.95, globenewswire.com reported 2025-03-11 that Submission for New Intended Use That Leverages Company’s Patented OneRF® Technology Platform Expected in May 2025 EDEN PRAIRIE, Minn., March 11, 2025 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablation to May 2025, which leverages the Company’s patented OneRF® Technology Platform.
Analysts’ Opinion of NMTC
Many brokerage firms have already submitted their reports for NMTC stocks, with Craig Hallum repeating the rating for NMTC by listing it as a “Hold.” The predicted price for NMTC in the upcoming period, according to Craig Hallum is $2 based on the research report published on March 29, 2022 of the previous year 2022.
NMTC Trading at -4.63% from the 50-Day Moving Average
After a stumble in the market that brought NMTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.00% of loss for the given period.
Volatility was left at 9.31%, however, over the last 30 days, the volatility rate increased by 11.10%, as shares sank -8.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.72% upper at present.
During the last 5 trading sessions, NMTC remain unchanged, which changed the moving average for the period of 200-days by -6.42% in comparison to the 20-day moving average, which settled at $1.0774. In addition, NeuroOne Medical Technologies Corp saw 23.50% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NMTC starting from Christianson Mark, who sale 2,189 shares at the price of $0.88 back on Jun 06 ’24. After this action, Christianson Mark now owns 295,035 shares of NeuroOne Medical Technologies Corp, valued at $1,918 using the latest closing price.
Christianson Mark, the Business Development Director of NeuroOne Medical Technologies Corp, sale 25,800 shares at $0.88 during a trade that took place back on Jun 05 ’24, which means that Christianson Mark is holding 297,224 shares at $22,663 based on the most recent closing price.
Stock Fundamentals for NMTC
Current profitability levels for the company are sitting at:
- -1.18 for the present operating margin
- 0.48 for the gross margin
The net margin for NeuroOne Medical Technologies Corp stands at -1.25. The total capital return value is set at -1.38. Equity return is now at value -195.50, with -116.72 for asset returns.
Based on NeuroOne Medical Technologies Corp (NMTC), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -29.47. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -20.9.
Currently, EBITDA for the company is -11.84 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 5.32. The receivables turnover for the company is 2.43for trailing twelve months and the total asset turnover is 0.89. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.58.
Conclusion
In conclusion, NeuroOne Medical Technologies Corp (NMTC) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
